CB-1158
- Generic Name
- CB-1158
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H22BN3O5
- CAS Number
- 2095732-06-0
- Unique Ingredient Identifier
- IFD73D535A
- Background
CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 18
- Registration Number
- NCT03910530
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Japan
🇯🇵National Cancer Center Hospital, Chuo Ku, Japan
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 15
- Registration Number
- NCT03837509
- Locations
- 🇺🇸
New York Oncology Hematology, Albany, New York, United States
🇺🇸Virginia Cancer Specialists-Fairfax, Fairfax, Virginia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT03361228
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸The University of Chicago Medicine, Chicago, Illinois, United States
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 149
- Registration Number
- NCT03314935
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers, Marietta, Georgia, United States
🇺🇸USA Mitchell Cancer Center, Mobile, Alabama, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 260
- Registration Number
- NCT02903914
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸BIDMC, Boston, Massachusetts, United States
🇺🇸MD Anderson, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.